Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13199189 | 0.89 | ACSS2 (0.51) | TSHRMAPK1ACSS2NPSR1KDM4E | |
| SCHEMBL30628323 | 0.84 | ACSS2 (0.48) | ACSS2NPSR1KDM4EPOLBLMNA | |
| SCHEMBL2012390 | 0.84 | ACSS2 (0.48) | ACSS2NPSR1KDM4EPOLBLMNA | |
| SCHEMBL31306494 | 0.84 | NPSR1 (0.50) | ACSS2SMN1; SMN2NPSR1KDM4EPOLB | |
| SCHEMBL17420520 | 0.83 | ACSS2 (0.47) | TSHRACSS2SMN1; SMN2NPSR1KDM4E | |
| SCHEMBL6161136 | 0.83 | CNR2 (0.50) | TSHRMAPK1SMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL17420423 | 0.83 | POLB (0.51) | ACSS2SMN1; SMN2NPSR1KDM4EPOLB | |
| SCHEMBL22165138 | 0.83 | TSHR (0.52) | TSHRMAPK1SMN1; SMN2NPSR1CYP3A4 | |
| SCHEMBL1657919 | 0.82 | ACSS2 (0.46) | TSHRMAPK1ACSS2NPSR1KDM4E | |
| SCHEMBL30914092 | 0.82 | MAPT (0.46) | TSHRMAPK1ACSS2SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO, INC. | 2025-06-12 | — | — | US | disclosed |
| US-12133852-B2 | ACSS2 inhibitors and methods of use thereof | EPIVARIO, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-20220305010-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2022-09-29 | — | — | US | disclosed |
| EP-3983386-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | Metabomed Ltd (IL) | 2022-04-20 | — | — | EP | disclosed |
| CN-114008025-A | ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-112601752-A | Novel inhibitors of MAP4K1 | 伊克诺斯科学公司 | 2021-04-02 | — | — | CN | disclosed |
| WO-2020230136-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020230136-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2020-11-19 | — | — | WO | disclosed |
| EP-3630778-A1 | NOVEL INHIBITORS OF MAP4K1 | Ichnos Sciences SA (CH) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215668-A1 | NOVEL INHIBITORS OF MAP4K1 | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | TSHR 3842/4885MAPK1 1469/4885ACSS2 1/4885 |
| US-20220305010-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | TSHR 3842/4885MAPK1 1469/4885ACSS2 1/4885 |
| US-12133852-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, GLS2, ADSS2 | TSHR 3842/4885MAPK1 1469/4885ACSS2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.